Novel Bivalent 99mTc-Complex with N-Methyl-Substituted Hydroxamamide as Probe for Imaging of Cerebral Amyloid Angiopathy.
Cerebral amyloid angiopathy (CAA) is characterized by the deposition of amyloid aggregates in the walls of the cerebral vasculature. Recently, the development of molecular imaging probes targeting CAA has been attracting much attention. We previously reported the 99mTc-hydroxamamide (99mTc-Ham) complex with a bivalent benzothiazole scaffold as a binding moiety for amyloid aggregates ([99mTc]BT2) and its utility for CAA-specific imaging. However, the simultaneous generation of two radiolabeled complexes derived from the geometric isomers was observed in the 99mTc-labeling reaction. It was recently reported that the complexation reaction of 99Tc with N-methyl-substituted Ham provided a single 99Tc-Ham complex consisting of two N-methylated Ham ligands with marked stability. In this article, we designed and synthesized a novel N-methylated bivalent 99mTc-Ham complex ([99mTc]MBT2) and evaluated its utility for CAA-specific imaging. N-Methyl substitution of [99mTc]BT2 prevented the generation of its isomer in the 99mTc-labeling reaction. Enhanced in vitro stability of [99mTc]MBT2 as compared with [99mTc]BT2 was observed. [99mTc]MBT2 showed very low brain uptake, which is favorable for CAA-specific imaging. An in vitro inhibition assay using β-amyloid aggregates and in vitro autoradiographic examination of brain sections from a Tg2576 mouse and a CAA patient showed a decline in the binding affinity for amyloid aggregates due to N-methylation of the 99mTc-Ham complex. These results suggest that the scaffold of the 99mTc-Ham complex may play important roles in the in vitro stability and the binding affinity for amyloid aggregates.
Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Shimpei
S
Iikuni
Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Masahiro
M
Ono
Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Hiroyuki
H
Watanabe
Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Masashi
M
Yoshimura
Department of Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan.
Hatsue
H
Ishibashi-Ueda
Department of Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center, Osaka, Japan.
Masafumi
M
Ihara
Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Hideo
H
Saji
J Nucl Med. 2009 Aug;50(8):1251-9
19617318
J Nucl Med. 2009 Nov;50(11):1887-94
19837759
Nucl Med Biol. 2005 Nov;32(8):799-809
16253804
Mol Pharm. 2014 Apr 7;11(4):1132-9
24673484
Ann Neurol. 2010 Oct;68(4):545-8
20865701
Stroke. 2010 Oct;41(10 Suppl):S139-43
20876490
Ann Neurol. 2007 Sep;62(3):229-34
17683091
J Nucl Med. 2013 May;54(5):723-31
23471310
Inorg Chem. 2011 Feb 7;50(3):992-8
21226472
Neurology. 2010 Feb 9;74(6):487-93
20142615
Bioconjug Chem. 2016 May 18;27(5):1314-23
27045547
Biomaterials. 2014 Feb;35(6):1967-76
24331706
Stroke. 2004 Nov;35(11 Suppl 1):2616-9
15459438
Neurology. 2001 Feb 27;56(4):537-9
11222803
J Clin Neurol. 2011 Mar;7(1):1-9
21519520
Stroke. 1987 Mar-Apr;18(2):311-24
3551211
Bioconjug Chem. 1999 Jan-Feb;10(1):9-17
9893958
J Zhejiang Univ Sci. 2004 Oct;5(10):1262-9
15362199
Brain Res. 2013 Jun 26;1519:19-30
23651976
Stroke. 2008 Apr;39(4):1127-33
18292383
J Nucl Med. 2013 Aug;54(8):1472-8
23740104
Neurosurg Focus. 2012 Apr;32(4):E7
22463117
J Med Chem. 2011 Dec 8;54(23 ):8085-98
22011144
J Neural Transm (Vienna). 2002 May;109(5-6):813-36
12111471
Sci Rep. 2016 May 16;6:25990
27181612
Neurology. 1996 Jun;46(6):1592-6
8649554
J Nucl Med. 2010 Jun;51(6):913-20
20501908
PLoS One. 2012;7(6):e38284
22675537
Mol Pharm. 2015 Aug 3;12 (8):2937-46
26065726
AJR Am J Roentgenol. 2004 Jun;182(6):1547-50
15150006
Ann Neurol. 2011 Dec;70(6):871-80
22190361